CA Patent

CA2801190A1 — Use of the sparc microenvironment signature in the treatment of cancer

Assigned to Abraxis Bioscience LLC · Expires 2011-12-08 · 14y expired

What this patent protects

The invention provides multiparametric anti-SPARC antibody-based techniques for predicting the response to chemotherapy.

USPTO Abstract

The invention provides multiparametric anti-SPARC antibody-based techniques for predicting the response to chemotherapy.

Drugs covered by this patent

Patent Metadata

Patent number
CA2801190A1
Jurisdiction
CA
Classification
—
Expires
2011-12-08
Drug substance claim
No
Drug product claim
No
Assignee
Abraxis Bioscience LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.